Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

British Columbia Extends Biosimilar Switching To Adalimumab

Follows Launch Of Five Humira Biosimilars In Canada In February

Executive Summary

British Columbia has expanded its biosimilar switching program to cover patients being treated with Humira in the Canadian province.

You may also be interested in...



British Columbia Adds Insulins To Its Biosimilar Switching Policy

Patients taking Humalog and NovoRapid will have six months to switch to their biosimilar equivalents after British Columbia added the rapid-acting insulins to its biosimilar switching policy.

Alberta Expands Biosimilar Switching With Adalimumab

Alberta has become the latest Canadian province to expand its biosimilar switching program to cover adalimumab biosimilars to Humira.

Third Canadian Province Follows On Biosimilar Switching

New Brunswick has become the latest Canadian province to introduce a biosimilar switching program, with the newly-introduced scheme covering several biologic molecules.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB150813

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel